Folletos de información educativa en migraña: satisfacción percibida en un grupo de pacientes / Migraine education brochures and patient-perceived satisfaction

Introducción: Los folletos informativos son una herramienta educativa habitual en la práctica neurológica diaria; mediante este mecanismo se pretende incrementar de primera mano los conocimientos que la población tiene sobre una enfermedad concreta, además de evitar fuentes de información erróneas. Las encuestas son el medio más empleado para conocer la satisfacción de los usuarios con los servicios recibidos. Objetivos: Evaluar la satisfacción percibida y establecer una retroalimentación informativa que valore la comprensión y la utilidad global de un folleto educativo sobre migraña. Material y métodos: Estudio abierto, prospectivo y multicéntrico sobre una población de pacientes diagnosticados de migraña en diversas consultas de neurología de la provincia de Alicante. En la visita basal se les entrega un folleto informativo de migraña confeccionado por el grupo de estudio para la cefalea de la Sociedad Valenciana de Neurología (CEFALIC). En la visita control se les solicita la cumplimentación de una encuesta personal y por escrito sobre la calidad global de la información incluida en el folleto. Resultados: Se incluye a un total de 257 pacientes diagnosticados de migraña (83% migraña episódica; 17% migraña crónica), con una edad media de 37,6 años. Confirmaron la lectura del folleto 207 paciente (80,5%) y no lo habían leído 50 pacientes (19,5%), bien por olvido bien por desinterés. Al 90% de los pacientes la lectura del folleto les pareció interesante y comprensible. El 76% de los encuestados opina que la lectura del folleto incrementa sus conocimientos sobre migraña. El 50% de los pacientes opina que el folleto resultó de utilidad para mejorar el control de su migraña. Conclusiones: La utilización de un folleto educativo sobre migraña resultó comprensible, además incrementó el conocimiento global de la enfermedad y en opinión de los pacientes resultó útil para mejorar el control de su migraña. La evaluación de la información educativa que prestamos a nuestros pacientes con migraña debe ser medida para descubrir las causas de descontento, determinar el nivel de calidad del servicio e investigar las posibilidades de mejora de calidad

Introduction: Brochures are commonly used as educational tools in daily neurological practice. They are provided to increase the general population's knowledge of a specific disease and also to combat sources of erroneous information. Surveys are the most commonly used method of ascertaining user satisfaction with services received. Objectives: This study will assess patient-perceived satisfaction and provide feedback to measure the comprehensibility and overall utility of an educational brochure on migraine. Material and methods: Open prospective multicentre study of a group of patients diagnosed with migraine in neurology clinics in Alicante province. During the initial visit, each patient received a migraine brochure prepared by the Valencian Society of Neurology's study group for headaches (CEFALIC). During a follow-up visit, they were then asked to fill out a personal survey on the overall quality of the information in the brochure. Results: We included a total of 257 patients diagnosed with migraine (83% episodic migraine; 17% chronic migraine); mean age was 37.6 years. Two hundred seven patients confirmed having read the brochure (80.5%); 50 patients (19.5%) either forgot to read it or had no interest in doing so. The brochure seemed interesting and easy to understand according to 90% of the patients. Seventy-six per cent of the respondents stated that reading the brochure increased their overall knowledge of migraine, while 50% of the patients found the brochure useful for improving migraine control. Conclusions: Patients found the migraine educational brochure to be comprehensible, a means of increasing overall knowledge of the disease, and useful for increasing control over migraines. Evaluations of the educational brochures that we provide to our patients with migraine should be studied to discover the causes of dissatisfaction, determine the level of quality of service, and investigate potential areas for improvement

Right temporal lobe variant of frontotemporal dementia.

We present two women with the right temporal lobe variant (RTLV) of frontotemporal dementia (FTD) and analyse the clinical features that are determined by the anatomical distribution of atrophy. Each of our patients displayed different clinical and radiological profiles which were in line with findings reported by other authors. One of two patients carries a novel mutation in the granulin gene. FTD is heterogeneous with regard to clinical manifestation, genetics, distribution of cortical atrophy and underlying disease. Its clinical manifestations are related to the distribution of the cortical atrophy. The RTLV of FTD is an uncommon entity. There is no consensus about its name despite the fact that its clinical and radiological features are well-defined and distinguish it from other types of FTD including semantic dementia.

Migraine education brochures and patient-perceived satisfaction.

INTRODUCTION: Brochures are commonly used as educational tools in daily neurological practice. They are provided to increase the general population's knowledge of a specific disease and also to combat sources of erroneous information. Surveys are the most commonly used method of ascertaining user satisfaction with services received. OBJECTIVES: This study will assess patient-perceived satisfaction and provide feedback to measure the comprehensibility and overall utility of an educational brochure on migraine. MATERIAL AND METHODS: Open prospective multicentre study of a group of patients diagnosed with migraine in neurology clinics in Alicante province. During the initial visit, each patient received a migraine brochure prepared by the Valencian Society of Neurology's study group for headaches (CEFALIC). During a follow-up visit, they were then asked to fill out a personal survey on the overall quality of the information in the brochure. RESULTS: We included a total of 257 patients diagnosed with migraine (83% episodic migraine; 17% chronic migraine); mean age was 37.6 years. Two hundred seven patients confirmed having read the brochure (80.5%); 50 patients (19.5%) either forgot to read it or had no interest in doing so. The brochure seemed interesting and easy to understand according to 90% of the patients. Seventy-six per cent of the respondents stated that reading the brochure increased their overall knowledge of migraine, while 50% of the patients found the brochure useful for improving migraine control. CONCLUSIONS: Patients found the migraine educational brochure to be comprehensible, a means of increasing overall knowledge of the disease, and useful for increasing control over migraines. Evaluations of the educational brochures that we provide to our patients with migraine should be studied to discover the causes of dissatisfaction, determine the level of quality of service, and investigate potential areas for improvement.

[The phenomenon of immigration within the European Community and its impact on neurological care in the Marina Baixa area, Alicante]. / El fenómeno de la inmigración en la Europa comunitaria y su impacto en la asistencia neurológica en el área de la Marina Baixa, Alicante.

INTRODUCTION: Immigration is shaping a new model of society, with new needs and demands, whose characteristics must guide health-care policies. AIM. To determine the repercussions of the phenomenon of immigration on the extra-hospital neurological care carried out in Department 16 of the Agencia Valenciana de Salud (Valencian Health Service) and how language problems affect visits. PATIENTS AND METHODS: We conducted a prospective study during 26 consecutive outpatient visits in the first three months of 2006. RESULTS: Of all the patients who were attended, 9.5% were foreigners. Of these, 77.7% came from EU countries. And of those from outside the Community, 13% were from Latin American countries, 5% came from European countries that do not belong to the EU and 5% were from Africa. Mean ages were 61.5 years for the EU group and 42.6 years for the other nationalities. The main reasons for visiting were headache and cognitive impairment. The poorer the quality of communication was, the longer the visit lasted. CONCLUSIONS: The high prevalence of immigrants from the EU, mostly elderly persons and with chronic neurological pathologies, together with the ageing of the autochthonous population, have led to a progressive growth in the demand for health care in our area. The language barrier makes clinical practice more complicated and results in an increase in the time needed for each patient. These facts must be taken into account when planning both the health care resources in our area and visiting times per patient.

Mononeuropatía múltiple asociada a tratamiento con pravastatina / Multiple mononeuropathy associated to treatment with pravastatin

Introducción. La neuropatía secundaria al tratamiento con estatinas se conoce desde 1994. aunque es una complicación poco frecuente. Habitualmente se trata de una polineuropatía axonal, predominantemente sensitiva, distal y simétrica, subaguda o crónica. Presentamos el segundo caso que se recoge en la bibliografía de mononeuritis múltiple asociada al uso de estatinas. Caso clínico. Mujer de 51 años que, tras iniciar tratamiento con pravastatina, presentó parestesias progresivas distales en miembros, de distribución asimétrica, con inestabilidad en la marcha. El estudio electromiográfico fue compatible con mononeuritis múltiple. Las pruebas complementarias realizadas para descartar otras causas de mononeuropatía múltiple fueron normales. La enferma mejoró al abandonar el tratamiento y empeoró de nuevo tras retomarlo. Con la suspensión definitiva de la pravastatina volvió a mejorar de forma progresiva hasta quedar prácticamente asintomática. Conclusiones. La relación entre el tratamiento con estatinas y la aparición de polineuropatía ha quedado establecida en distintos estudios epidemiológicos de casos y controles. No sólo se puede presentar como la clásica polineuropatía distal y simétrica, sino que se han descrito formas clínicas atípicas, incluido algún caso como el nuestro de mononeuropatía múltiple. El riesgo de desarrollar esta complicación es pequeño y se ve compensado por los beneficios cardiovasculares de las estatinas, aunque posiblemente en un futuro se verá con más frecuencia, dado el uso creciente de estos fármacos. Es importante tener en cuenta esta causa de neuropatía, dada su reversibilidad potencial

Introduction. The first reports of neuropathy due to treatment with statins appeared in 1994, although it is an infrequent complication. It usually consists of an axonal polyneuropathy, which is predominantly sensory, distal and symmetric, and may be subacute or chronic. We present here the second case reported in the literature of multiple mononeuropathy associated to the use of statins. Case report. A 51-year-old female patient who, after beginning therapy with pravastatin, presented with progressive, asymmetrically distributed, distal paresthesias in the limbs and an unstable gait. An electromyographic study was compatible with multiple mononeuritis. Results of complementary tests that were carried out to preclude other causes of multiple mononeuropathy were normal. The patient’s condition improved on withdrawing treatment with the drug and it became worse again when therapy was restarted. When pravastatin therapy was stopped for good, the patient's condition progressively improved until she was practically free of symptoms. Conclusions. The relationship between treatment with statins and the appearance of polyneuropathy has been proved in different epidemiological case-control studies. It does not only appear as the classical distal symmetrical olyneuropathy, but has also been reported as taking on atypical clinical forms including a few cases, like ours, of multiple mononeuropathy. The risk of developing this complication is low and is offset by the cardiovascular benefits offered by statins, although it may become more common in the future due to the increasing rate of use of these agents. It is important to bear this cause of neuropathy in mind, given the fact that it is potentially reversible

[Multiple mononeuropathy associated to treatment with pravastatin]. / Mononeuropatía múltiple asociada a tratamiento con pravastatina.

INTRODUCTION: The first reports of neuropathy due to treatment with statins appeared in 1994, although it is an infrequent complication. It usually consists of an axonal polyneuropathy, which is predominantly sensory, distal and symmetric, and may be subacute or chronic. We present here the second case reported in the literature of multiple mononeuropathy associated to the use of statins. CASE REPORT: A 51-year-old female patient who, after beginning therapy with pravastatin, presented with progressive, asymmetrically distributed, distal paresthesias in the limbs and an unstable gait. An electromyographic study was compatible with multiple mononeuritis. Results of complementary tests that were carried out to preclude other causes of multiple mononeuropathy were normal. The patient's condition improved on withdrawing treatment with the drug and it became worse again when therapy was restarted. When pravastatin therapy was stopped for good, the patient's condition progressively improved until she was practically free of symptoms. CONCLUSIONS: The relationship between treatment with statins and the appearance of polyneuropathy has been proved in different epidemiological case-control studies. It does not only appear as the classical distal symmetrical polyneuropathy, but has also been reported as taking on atypical clinical forms including a few cases, like ours, of multiple mononeuropathy. The risk of developing this complication is low and is offset by the cardiovascular benefits offered by statins, although it may become more common in the future due to the increasing rate of use of these agents. It is important to bear this cause of neuropathy in mind, given the fact that it is potentially reversible.

[Retinopathy secondary to treatment with Interferon beta-1a in a patient with multiple sclerosis]. / Retinopatía secundaria a tratamiento con interferón beta 1a en paciente con esclerosis múltiple.

INTRODUCTION: Although visual symptoms of multiple sclerosis (MS) are very frequent, they are rarely related with treatment with interferon. This is the first case reported in the literature of retinopathy associated with subcutaneous interferon beta-1a, and the second related to interferons in MS. CASE REPORT: A 30-year-old female diagnosed with relapsing-remitting MS who, at 3 months after starting treatment with subcutaneous interferon beta-1a (44 microg/3 times a week), displayed visual disorders. Retinal lesions in the form of cotton wool spots were found as symptoms of microinfarctions in the retina. The lesions got better after stopping treatment and the patient was found to be asymptomatic. CONCLUSIONS: The existence of retinopathy secondary to interferon has been known in the treatment of hepatitis C and neoplasias with interferon alfa since 1990. Despite being a frequently occurring complication, it is usually a mild condition and disappears on withdrawing treatment, or even if it is continued. It is attributed to deposits of immunocomplexes and complement activation in the blood vessels of the retina. Only one other case associated to treatment of MS with interferon beta has been reported in the literature, more specifically related to subcutaneous interferon beta-1b. The clinical characteristics of both cases are identical to those associated to interferon alfa. Despite the fact that the frequency of appearance seems to be lower than in the case of interferon alfa, the physician must bear in mind the possibility encountering this complication.

[Ambulatory neurological care in the Marina Baixa area, Alicante]. / Asistencia neurológica ambulatoria en el área de la Marina Baixa, Alicante.

INTRODUCTION: The demand for neurological care depends on the type of population to be attended, among other variables. The Marina Baixa area, which includes towns such as Altea and Benidorm, has its own peculiar characteristics due to its being one of the places that is often chosen by pensioners from northern and central Spain and Europe to set up residence. AIM: The aim of this study was to determine the characteristics of the ambulatory neurological care in our health area. PATIENTS AND METHODS: Data on 1,000 patients attended in the Neurological Clinic at the Specialty Centre in Benidorm (age, sex, reason for visit, tests requested and destination on discharge) were recorded prospectively and consecutively. RESULTS: The mean age was 58.04 years (range 14-94) and 56.4% were females. 25% of the patients attended were over 75 years old. The main reasons for visiting were headache (28.2%) and cognitive impairment (21%). 26.5% were first-time visits, with a mean age of 55.02 years, which is significantly lower than that of the review patients (59.12 years; p = 0.003). 15.6% of the patients were discharged from hospital. A prolonged follow-up was foreseen for over 50% of them. The demand for care in 2003 was 27.5 per 1,000 inhabitants/year in the population above the age of 14 years. CONCLUSIONS: The higher the mean age of the population is, the greater the prevalence of neurodegenerative diseases will become and the more demand there will be for ambulatory care. Resources must be adjusted to this new situation and there is also a need to adopt the most suitable model of health care for chronic neurological patients.

[Ischemic stroke as a presentation of essential thrombocythemia. Four case reports]. / Ictus isquémico como forma de presentación de trombocitemia esencial. A propósito de cuatro casos.

INTRODUCTION: Essential thrombocythemia (ET) is a myelodysplastic syndrome that constitutes an infrequent cause of ischemic stroke. Few clinical reports have been published describing the clinical onset of ET in the form of a vascular accident. CASE REPORT: We describe four cases of patients with no known haematological pathology who began with an ischemic stroke and were later diagnosed as suffering from ET, following an aetiological investigation. The patients were all young, under 45 years of age, with no significant vascular risk factors, who presented a clinical picture of ischemic stroke and platelet counts above normal values, although in two cases they were below 600 x 10(9)/L. As they progressed, their platelet counts were constantly above this threshold and a diagnosis of ET was reached. CONCLUSIONS: Although ET is an infrequent cause of ischemic stroke, it must be taken into account even in young patients and when platelet counts do not exceed 600 x 10(9)/L. Antiplatelet drug therapy must be indicated in all cases and the clinician must evaluate the suitability of cytoreductive therapy in patients with a high risk of thrombotic event recurrence, especially if platelet counts are above 600 x 10(9)/L.

Ictus isquémico como forma de presentación de trombocitemia esencial. A propósito de cuatro casos / Ischemic stroke as a presentation of essential thrombocythemia. Four case reports

Introducción. La trombocitemia esencial (TE) es un síndrome mielodisplásico que constituye una causa infrecuente de ictus isquémico. Hay escasas descripciones clínicas de debut clínico de una TE en forma de accidente vascular agudo. Casos clínicos. Se presentan cuatro casos de pacientes sin patología hematológica conocida que debutan con un accidente vascular cerebral isquémico y en los que la investigación etiológica llevó al diagnóstico de TE. Se trata de pacientes jóvenes, menores de 45 años todos ellos, sin factores de riesgo vascular significativos, que presentan clínica de ictus isquémico y cifras de plaquetas por encima de lo normal, aunque en dos casos por debajo de 600 × 10 elevado a 9/L. En la evolución de todos ellos, las cifras de plaquetas superaron ese umbral de forma mantenida y se llegó al diagnóstico de TE. Conclusiones. Aunque la TE es una causa infrecuente de accidente vascular cerebral isquémico, debe tenerse en cuenta incluso en pacientes jóvenes y cuando las cifras de plaquetas no superen las 600 × 10 elevado a 9/L. Se debe indicar el tratamiento antiagregante en todos los casos y valorar el tratamiento citorreductor en pacientes de alto riesgo de recidiva de fenómenos trombóticos, fundamentalmente, si las cifras de plaquetas superan las 600 × 10 elevado a 9/L (AU)

Introduction. Essential thrombocythemia (ET) is a myelodysplastic syndrome that constitutes an infrequent cause of ischemic stroke. Few clinical reports have been published describing the clinical onset of ET in the form of a vascular accident. Case reports. We describe four cases of patients with no known haematological pathology who began with an ischemic stroke and were later diagnosed as suffering from ET, following an aetiological investigation. The patients were all young, under 45 years of age, with no significant vascular risk factors, who presented a clinical picture of ischemic stroke and platelet counts above normal values, although in two cases they were below 600 × 109 /L. As they progressed, their platelet counts were constantly above this threshold and a diagnosis of ET was reached. Conclusions. Although ET is an infrequent cause of ischemic stroke, it must be taken into account even in young patients and when platelet counts do not exceed 600 × 109 /L. Antiplatelet drug therapy must be indicated in all cases and the clinician must evaluate the suitability of cytoreductive therapy in patients with a high risk of thrombotic event recurrence, especially if platelet counts are above 600 × 109 /L (AU)

[Multiple sclerosis incidence in the Alcoi Health district. 12-year-long study (1986-1997)]. / Incidencia de la esclerosis múltiple en el área sanitaria de Alcoi. Estudio de 12 años (1986-1997).

INTRODUCTION: To date, epidemiological studies on multiple sclerosis in Spain have been basically prevalence studies, and the data on incidence recorded have been the result of different methodologies, with no definition of the criteria for inclusion. OBJECTIVE: To carry out a study of incidence with prospective collection/review of cases over a prolonged period of time. PATIENTS AND METHODS: Over 12 years, between 1 March 1986 and 31 December 1997, we collected data prospectively for patients with a definite diagnosis of multiple sclerosis. The year of incidence was considered to be when the patient fulfilled clinical criteria for diagnosis of the disease. RESULTS: On 31 December 1997 in the Alcoi Health District there were 54 patients with clinically defined multiple sclerosis (a prevalence of 41.28 cases per 100,000 inhabitants). Of these, 45 patients were diagnosed during the period studied, with an average incidence of 2.82 cases per 100,000 inhabitants per year. Only 15 patients were confirmed before 1986. CONCLUSIONS: This is the most prolonged study of the incidence of multiple sclerosis carried out in Spain. The figures found for incidence are in contrast to those found in previous years for prevalence and incidence. Analysis of the data suggests that the incidence of multiple sclerosis in the Alcoi district has changed and has increased since the second half of the 1980s.

[The prevalence of multiple sclerosis in the Alcoi Health district]. / Prevalencia de la esclerosis múltiple en el área sanitaria de Alcoi.

INTRODUCTION: The epidemiological studies done in Spain in recent years show higher figures for the prevalence of multiple sclerosis than before. Spain is therefore now in the area with a high risk of contracting the disease. OBJECTIVE: We have made a new study to confirm the current prevalence of the disorder in the Alcoi Health District. PATIENTS AND METHODS: Between 1 March 1986 and the prevalence day, 31 December 1997 we recorded the patients with definite or probable multiple sclerosis, as defined on Poser's criteria, after intensive fieldwork and reevaluation of all possible patients by a neurologist from the Neurology Unit. On the prevalence day there were 130,786 inhabitants in the district. RESULTS: On the prevalence day we found 54 patients with definite multiple sclerosis and no patient with probable multiple sclerosis. The rate of prevalence was 41.28 cases per 100,000 inhabitants (95% CI: 31-53.6). During the study we counted an incidence of 45 cases with an average rate of 2.82 cases per 100,000 inhabitants per year. We also describe the clinical characteristics of the patients. CONCLUSIONS: The rate of prevalence found is much higher than that described for the district in studies using similar methodology. This increase, together with the discrepancy between the incidence found and the prevalence, makes us consider that possibly the prevalence has increased in recent years.

Incidencia de la esclerosis múltiple en el área sanitaria de Alcoi. Estudio de 12 años (1986-1997) / The incidence of multiple sclerosis in the Alcoi health district. A 12 year study (1986-1997)

Introducción. Los estudios epidemiológicos sobre esclerosis múltiple en España han sido hasta la fecha estudios fundamentalmente de prevalencia, y los datos de incidencia descritos se han recogido con metodología dispar, sin precisar los criterios de inclusión.Objetivo. Realizar un estudio de incidencia con recogida prospectiva de los casos a lo largo de un período prolongado de tiempo. Pacientes y métodos. A lo largo de 12 años, desde el 1 de marzo de 1986 al 31 de diciembre de 1997, se han recogido de forma prospectiva aquellos enfermos con diagnóstico de esclerosis múltiple definida. Se ha considerado como año de incidencia aquel en el que los pacientes cumplían criterios clínicos de la enfermedad. Resultados. El 31 de diciembre de 1997 había en el área de Alcoi 54 pacientes con esclerosis múltiple clínicamente definida (prevalencia de 41,28 casos por 100.000 habitantes). De ellos, 45 pacientes fueron incidentes a lo largo del período del estudio, con una tasa media de incidencia de 2,82 casos por 100.000 habitantes y año. Únicamente 15 pacientes fueron incidentes con anterioridad a 1986. Conclusiones. Este estudio es el más prolongado de los realizados sobre la incidencia de la esclerosis múltiple en España. Las cifras de incidencia halladas contrastan con los datos de prevalencia y la incidencia de los años anteriores. El análisis de los datos sugiere que la incidencia de la esclerosis múltiple en el área de Alcoi ha variado, incrementándose desde la segunda mitad de los años 80 (AU)

Prevalencia de la esclerosis múltiple en el área sanitaria de Alcoi / The prevalence of multiple sclerosis in the Alcoi health district

Introducción. Los estudios epidemiológicos llevados a cabo los últimos años en España muestran cifras de prevalencia de la esclerosis múltiple superiores a las anteriormente descritas, y sitúan a nuestro país dentro de un área de riesgo elevado de padecer la enfermedad. Objetivo. Se ha realizado un nuevo estudio en el área sanitaria de Alcoi para comprobar la prevalencia actual de la enfermedad. Pacientes y métodos. Desde el 1 de marzo de 1986 hasta el día de prevalencia, el 31 de diciembre de 1997, se han recogido aquellos pacientes con diagnóstico de esclerosis múltiple definida o probable según los criterios de Poser, tras realizar un intensivo trabajo de campo y reevaluar a todos los posibles pacientes por un neurólogo de la Unidad de Neurología. El día de prevalencia el número de habitantes del área era 130.786. Resultados. El día de prevalencia se encontraron 54 pacientes con esclerosis múltiple definida y ningún paciente con esclerosis múltiple probable. La tasa de prevalencia fue de 41,28 casos por 100.000 habitantes (IC del 95 por ciento: 31-53,6). A lo largo del estudio se contabilizaron 45 casos incidentes con una tasa media de 2,82 casos por 100.000 habitantes y año. Se describen asimismo las características clínicas de los pacientes. Conclusiones. La tasa de prevalencia hallada es muy superior a la descrita previamente en la zona con estudios de similar metodología. Este incremento, junto a la discrepancia entre la incidencia encontrada y la prevalencia, hacen pensar en la posibilidad de un aumento de la prevalencia en los últimos años (AU)